Related Experiment Video
Updated: May 19, 2026
10:28
Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
Published on: March 15, 2022
Dipyridamole in antithrombotic treatment
1Department of Biophysics, Leibniz University of Hannover, Hannover, Germany. eisert.wolfgang@mh-hannover.de
Advances in Cardiology
|August 22, 2012
Summary
Dipyridamole enhances natural antithrombotic systems and improves tissue perfusion, offering benefits beyond platelet inhibition. Extended-release formulations may protect against oxidative stress and inflammation.
Area of Science:
- Pharmacology and Vascular Biology
- Thrombosis and Hemostasis
Background:
- Dipyridamole's antithrombotic activity was discovered 50 years ago, predating understanding of thrombus formation complexity.
- Historically, focus was on platelet inhibition for arterial thrombus prevention, often using in vitro systems lacking key hemostatic components.
Purpose of the Study:
- To elucidate dipyridamole's mechanisms beyond direct platelet inhibition.
- To explore its role in improving tissue perfusion and function in hypoperfused states.
- To evaluate newer formulations and their impact on vascular and tissue protection.
Main Methods:
- In vivo experiments to assess antithrombotic activity and tissue perfusion.
- Analysis of dipyridamole's effects on endogenous antithrombotic systems and prothrombotic processes.
- Review of recent clinical trials on specific dipyridamole formulations.
Main Results:
- Dipyridamole amplifies endogenous antithrombotic systems and modulates prothrombotic factors.
- Experimental evidence shows improved perfusion in chronic hypoperfused tissue, independent of vasodilation.
- Clinical trials confirm benefits of sufficient plasma concentrations; antioxidant and anti-inflammatory effects are highlighted.
Conclusions:
- Dipyridamole's benefits extend beyond antithrombotic effects, involving tissue protection via radical scavenging and inflammation reduction.
- Extended-release dipyridamole may offer protection against oxidative and metabolic stress without significantly increasing bleeding risk.
Related Concept Videos
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:29Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...